Get the Stockscreener App
2.85
4.36%
-0.13
Pre-market:
2.90
0.05
+1.75%
Adial Pharmaceuticals Inc stock is traded at $2.85, with a volume of 246.23K.
It is down -4.36% in the last 24 hours and up +106.52% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
See More
Previous Close:
$2.98
Open:
$3.12
24h Volume:
246.23K
Relative Volume:
0.56
Market Cap:
$6.24M
Revenue:
-
Net Income/Loss:
$-7.77M
P/E Ratio:
-0.2877
EPS:
-9.9046
Net Cash Flow:
$-6.52M
1W Performance:
+28.96%
1M Performance:
+106.52%
6M Performance:
-58.42%
1Y Performance:
-67.44%
1-Day Range:
$2.70
$3.12
1-Week Range:
$2.11
$5.17
52-Week Range:
$1.31
$18.90
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
2.85 | 6.24M | 0 | -7.77M | -6.52M | -9.9046 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
ADIL stock eyes best day in over 5 years — major pipeline overhaul and $64M raise fuel rally - MSN
ADIL Initiates Coverage by LUCID CAPITAL MARKETS -- Rating Set t - GuruFocus
Lucid Capital Markets initiates Adial Pharmaceuticals stock with buy rating on colitis drug potential - Investing.com UK
Adial Pharmaceuticals (ADIL) Holds Steady at $2.98 as Consolidation NarrowsIchimoku Kumo Twist - newsline.com
ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally - Stocktwits
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Adial broadens pipeline with Azora acquisition and up to $64 million financing - The Pharma Letter
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) Acquires Azora Therapeutics and Sec - GuruFocus
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. - ChartMill
Adial Pharmaceuticals (ADIL) Acquires Azora Therapeutics to Enha - GuruFocus
Adial Pharmaceuticals Announces Acquisition Of Azora Therapeutics And Up To $64 Million Financing - TradingView
Adial Pharmaceuticals, Inc. (ADIL) Stock: Strategic Acquisition Positions Company for Clinical Growth - parameter.io
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Adial Pharmaceuticals Acquires Azora and Raises $26.8M PIPE, With More on Milestones - TradingView
Adial Pharmaceuticals acquires Azora Therapeutics for $32M By Investing.com - Investing.com South Africa
Adial (NASDAQ: ADIL) acquires Azora and lines up up to $64M for UC drug - Stock Titan
Adial Pharmaceuticals acquires Azora Therapeutics for $32M - Investing.com
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing - GlobeNewswire
Colon‑targeted ulcerative colitis drug draws up to $64M funding - Stock Titan
Adial's Acquisition of Azora Boosts Stock Price by 110% - Intellectia AI
Adial Pharmaceuticals(ADIL) Stock Options Chain | Quotes & News - Moomoo
Adial Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
ADIL Q1 2026 Earnings: Narrowed Loss Beats Expectations as Biotech Advances PipelineRevenue Inflection Point - newsline.com
Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break - Bez Kabli
Adial Pharmaceuticals (ADIL) Surges 7.69%: Breaking Above Key SupportIchimoku Kumo Break - newsline.com
Adial Pharmaceuticals (ADIL) Drops 9.57% as Selling Pressure Mounts Near Key SupportDescending Triangle - The Legal Advocate
Adial Pharmaceuticals (ADIL) Q1 2026 Earnings: Narrower-Than-Expected Loss as Operational Progress ContinuesROIC Trend Report - newsline.com
ADIL Q1 2026 Earnings: Narrowed Loss Beats Estimates, but Market Remains CautiousEPS Revision Trend - newsline.com
ADIL Q1 2026 Earnings: Narrowing Loss Beats Estimates, But Stock Declines Amid No RevenuePost-Earnings Reaction - Newser
Adial Pharmaceuticals lead drug fits new policy mood as bipartisan bill signals broader lens on alcohol use disorder - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is Adial Pharmaceuticals, Inc. (ADIL) Stock Down Today? - Meyka
Why Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) Stock Up Today? - Meyka
Armistice Capital/Steven Boyd report 4.99% stake in Adial (NASDAQ: ADIL) - Stock Titan
Maxim Group Maintains Adial Pharmaceuticals(ADIL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Adial Pharmaceuticals 1Q Loss $2M >ADIL - Moomoo
The quiet strength in Adial Pharma (ADIL) business model (+4.20%) 2026-05-11Community Chart Signals - Newser
Adial Pharmaceuticals: Runway to Fund Operating Expenses Into 2nd Half of 2026 >ADIL - Moomoo
Adial Pharmaceuticals Q1 Net Income USD2 Million - TradingView
Adial Pharmaceuticals Reports Q1 2026 Results, Advances AD04 for Alcohol Use Disorder with FDA and European Developments 12 - Minichart
Adial Pharmaceuticals (NASDAQ: ADIL) details evolving AD04 development and IP - Stock Titan
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update - ChartMill
Adial Pharmaceuticals Q1 2026 10-Q Report: Clinical Development of AD04 for Alcohol Use Disorder, Financial Results, and Liquidity Update - Minichart
Adial Pharmaceuticals Inc (ADIL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Adial Pharmaceuticals Inc expected to post a loss of $1.21 a shareEarnings Preview - TradingView
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):